Determinants of early triage for hospitalization in myeloproliferative neoplasm (<scp>MPN)</scp> patients with <scp>COVID</scp>‐19

Barbui, Tiziano; Carobbio, Alessandra; Ghirardi, Arianna; Iurlo, Alessandra; Sobas, Marta; Elli, Elena Maria; Rumi, Elisa; Stefano, Valerio De; Lunghi, Francesca; Marchetti, Monia; Daffini, Rosa; Kabat, Mercedes Gasior; Cuevas, Beatriz; Fox, María Laura; Andrade‐Campos, Marcio; Palandri, Francesca; Guglielmelli, Paola; Benevolo, Giulia; Harrison, Claire; Foncillas, María Ángeles; Bonifacio, Massimiliano; Alvarez‐Larrán, Alberto; Kiladjian, Jean‐Jacques; Calderón, Estefanía Bolaños; Patriarca, Andrea; Cervantes, Keina Quiroz; Grießhammer, Martin; García-Gutiérrez, Valentín; Sanchez, Alberto Marin; Mazo, Elena Magro; Carli, Giuseppe; Hernández‐Boluda, Juan Carlos; Osorio, Sonia; Carreño‐Tarragona, Gonzalo; Serrano, Miguel Sagues; Kušec, Rajko; Elorza, Begoña Navas; Angona, Anna; Cirici, Blanca Xicoy; Abadia, Emma Lopez; Koschmieder, Steffen; Cattaneo, Daniele; Bucelli, Cristina; Cichocka, Edyta; Nałęcz, Anna Kulikowska de; Cavalca, Fabrizio; Borsani, Oscar; Betti, Silvia; Bellini, Marta; Curto-García, Natalia; Vannucchi, Alessandro M.

doi:10.1002/ajh.26732

Cited by 7 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, these incidences are superior to those reported in patients with more aggressive hematological neoplasms, in which Covid19 infection was severe in 60.7% of vaccinated patients [ 13 ]. A high NLR ratio, suggestive for a high degree of inflammation, was also associated with hospitalization and death, as already noted [ 14 ].…”

Section: Discussionsupporting

confidence: 73%

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

et al. 2023

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 73%

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

et al. 2023

View full text Add to dashboard Cite

“…NLR is an emerging and promising marker of inflammation ( 18 ), associated with adverse outcomes in various conditions, from sepsis ( 19 ), to cardiovascular diseases ( 20 – 22 ), and thrombosis in particular ( 23 , 24 ). It is also a strong predictor of acute COVID-19 severity and outcome ( 25 , 26 ), that in their turn are associated with SARS-CoV-2-induced activation of platelets, neutrophils, and endothelium ( 27 ).…”

Section: Discussionmentioning

confidence: 99%

Clinical variables associated with late-onset thrombotic and cardiovascular events, after SARS-CoV-2 infection, in a cohort of patients from the first epidemic wave: an 18-month analysis on the “Surviving-COVID” cohort from Bergamo, Italy

Benatti,

Venturelli,

Crotti

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

ImportancePopulation studies have recorded an increased, unexplained risk of post-acute cardiovascular and thrombotic events, up to 1 year after acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.ObjectivesTo search for clinical variables and biomarkers associated with late post-acute thrombotic and cardiovascular events after SARS-CoV-2 infection.DesignRetrospective cohort study.SettingThird-level referral hospital in Bergamo (Italy).ParticipantsAnalysis of an existing database of adult patients, who received care for SARS-CoV-2 infection at our institution between 20 February and 30 September 2020, followed up on a single date (“entry date”) at 3–6 months.ExposureInitial infection by SARS-CoV-2.Main outcomes and measuresPrimary outcome: occurrence, in the 18 months after entry date, of a composite endpoint, defined by the International Classification of Diseases—9th edition (ICD-9) codes for at least one of: cerebral/cardiac ischemia, venous/arterial thrombosis (any site), pulmonary embolism, cardiac arrhythmia, heart failure. Measures (as recorded on entry date): history of initial infection, symptoms, current medications, pulmonary function test, blood tests results, and semi-quantitative radiographic lung damage (BRIXIA score). Individual clinical data were matched to hospitalizations, voluntary vaccination against SARS-CoV-2 (according to regulations and product availability), and documented reinfections in the following 18 months, as recorded in the provincial Health Authority database. A multivariable Cox proportional hazard model (including vaccine doses as a time-dependent variable) was fitted, adjusting for potential confounders. We report associations as hazard ratios (HR) and 95% confidence intervals (CI).ResultsAmong 1,515 patients (948 men, 62.6%, median age 59; interquartile range: 50–69), we identified 84 endpoint events, occurring to 75 patients (5%): 30 arterial thromboses, 11 venous thromboses, 28 arrhythmic and 24 heart failure events. From a multivariable Cox model, we found the following significant associations with the outcome: previous occurrence of any outcome event, in the 18 months before infection (HR: 2.38; 95% CI: 1.23–4.62); BRIXIA score ≥ 3 (HR: 2.43; 95% CI: 1.30–4.55); neutrophils-to-lymphocytes ratio ≥ 3.3 (HR: 2.60; 95% CI: 1.43–4.72), and estimated glomerular filtration rate < 45 ml/min/1.73 m2 (HR: 3.84; 95% CI: 1.49–9.91).Conclusions and relevanceWe identified four clinical variables, associated with the occurrence of post-acute thrombotic and cardiovascular events, after SARS-CoV-2 infection. Further research is needed, to confirm these results.

show abstract

“…The effectiveness of the FROM infrastructure was tested during the COVID‐19 pandemic, which began in Europe in January 2020 and proved extremely lethal in the city and region of Bergamo. Many uncertainties surrounded the management of patients with MPNs and led us to urgently involve hematology centers across Europe to gather information on the impact of the virus on vulnerable MPN patients 6,7 . After IRB approval, data on the medical history of 900 patients were reported via electronic Case Report Forms (e‐CRFs), and the results were promptly shared with scientific societies such as the American Society of Hematology (ASH), which had organized a panel of MPN experts to gather information to provide appropriate management guidelines.…”

mentioning

confidence: 99%

Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID‐19

Abstract: In the clinical course of COVID-19, the disease is primarily driven by the replication of SARS-CoV-2 and subsequently includes a dysregu-

Cited by 7 publications

References 5 publications

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

Clinical variables associated with late-onset thrombotic and cardiovascular events, after SARS-CoV-2 infection, in a cohort of patients from the first epidemic wave: an 18-month analysis on the “Surviving-COVID” cohort from Bergamo, Italy

Paving the path for ongoing clinical research and education in post retirement age

Contact Info

Product

Resources

About